152 related articles for article (PubMed ID: 14502496)
21. Inhibitory effects of 2-substituted-1-naphthol derivatives on cyclooxygenase I and II.
Kongkathip B; Sangma C; Kirtikara K; Luangkamin S; Hasitapan K; Jongkon N; Hannongbua S; Kongkathip N
Bioorg Med Chem; 2005 Mar; 13(6):2167-75. PubMed ID: 15727869
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Najafnia L; Daraee B; Dadrass OG; Hedayati M
Bioorg Med Chem Lett; 2007 Oct; 17(20):5634-7. PubMed ID: 17822894
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors.
Cusan C; Spalluto G; Prato M; Adams M; Bodensieck A; Bauer R; Tubaro A; Bernardi P; Da Ros T
Farmaco; 2005 Apr; 60(4):327-32. PubMed ID: 15848208
[TBL] [Abstract][Full Text] [Related]
24. A CoMFA study of COX-2 inhibitors with receptor based alignment.
Datar PA; Coutinho EC
J Mol Graph Model; 2004 Dec; 23(3):239-51. PubMed ID: 15530820
[TBL] [Abstract][Full Text] [Related]
25. 2D QSAR consensus prediction for high-throughput virtual screening. An application to COX-2 inhibition modeling and screening of the NCI database.
Baurin N; Mozziconacci JC; Arnoult E; Chavatte P; Marot C; Morin-Allory L
J Chem Inf Comput Sci; 2004; 44(1):276-85. PubMed ID: 14741037
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2.
Riendeau D; Salem M; Styhler A; Ouellet M; Mancini JA; Li CS
Bioorg Med Chem Lett; 2004 Mar; 14(5):1201-3. PubMed ID: 14980665
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.
Khanapure SP; Garvey DS; Young DV; Ezawa M; Earl RA; Gaston RD; Fang X; Murty M; Martino A; Shumway M; Trocha M; Marek P; Tam SW; Janero DR; Letts LG
J Med Chem; 2003 Dec; 46(25):5484-504. PubMed ID: 14640557
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and effects on the COX-1 and COX-2 activity in human whole blood ex vivo of derivatives containing the [1]benzothienol-[3, 2-d]pyrimidin-4-one heterocyclic system.
Santagati A; Granata G; Marrazzo A; Santagati M
Arch Pharm (Weinheim); 2003 Sep; 336(9):429-35. PubMed ID: 14528491
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors.
Martić M; Tatić I; Marković S; Kujundzić N; Kostrun S
Eur J Med Chem; 2004 Feb; 39(2):141-51. PubMed ID: 14987823
[TBL] [Abstract][Full Text] [Related]
30. Structural approach for COX-2 inhibition.
Michaux C; Charlier C
Mini Rev Med Chem; 2004 Aug; 4(6):603-15. PubMed ID: 15279594
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase (COX) inhibitors: a comparative QSAR study.
Garg R; Kurup A; Mekapati SB; Hansch C
Chem Rev; 2003 Mar; 103(3):703-32. PubMed ID: 12630850
[No Abstract] [Full Text] [Related]
32. Perspective assessment of COX-1 and COX-2 selectivity of nonsteroidal anti-inflammatory drugs from clinical practice: use of genetic function approximation.
Zambre AP; Ganure AL; Shinde DB; Kulkarni VM
J Chem Inf Model; 2007; 47(2):635-43. PubMed ID: 17256838
[TBL] [Abstract][Full Text] [Related]
33. 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.
Biava M; Porretta GC; Cappelli A; Vomero S; Manetti F; Botta M; Sautebin L; Rossi A; Makovec F; Anzini M
J Med Chem; 2005 May; 48(9):3428-32. PubMed ID: 15857149
[TBL] [Abstract][Full Text] [Related]
34. In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Shin SS; Byun Y; Lim KM; Choi JK; Lee KW; Moh JH; Kim JK; Jeong YS; Kim JY; Choi YH; Koh HJ; Park YH; Oh YI; Noh MS; Chung S
J Med Chem; 2004 Feb; 47(4):792-804. PubMed ID: 14761182
[TBL] [Abstract][Full Text] [Related]
35. Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.
Ouellet M; Falgueyret JP; Percival MD
Biochem J; 2004 Feb; 377(Pt 3):675-84. PubMed ID: 14510637
[TBL] [Abstract][Full Text] [Related]
36. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri.
Likhitwitayawuid K; Sawasdee K; Kirtikara K
Planta Med; 2002 Sep; 68(9):841-3. PubMed ID: 12357401
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Apr; 13(7):2459-68. PubMed ID: 15755648
[TBL] [Abstract][Full Text] [Related]
38. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site?
Soliva R; Almansa C; Kalko SG; Luque FJ; Orozco M
J Med Chem; 2003 Apr; 46(8):1372-82. PubMed ID: 12672237
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for selective inhibition of COX-2 by nimesulide.
Fabiola GF; Pattabhi V; Nagarajan K
Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
[TBL] [Abstract][Full Text] [Related]
40. QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors.
Narsinghani T; Chaturvedi SC
Bioorg Med Chem Lett; 2006 Jan; 16(2):461-8. PubMed ID: 16290292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
